Polypharmacy in SLE: How Real Is the Problem?

This Reading Room is a collaboration between MedPage Today® and:

Investigators have examined the rates of polypharmacy in adults with systemic lupus erythematosus (SLE) -- and made suggestions for how to address the notoriously challenging issue with patients.

The cross-sectional study, which included 451 participants, appears in Arthritis Care & Research.

Co-author Laura Plantinga, PhD, associate professor of medicine at the University of California, San Francisco, discussed the study with the Reading Room. The exchange has been edited for length and clarity.

Why is polypharmacy among patients with SLE an important issue to study?

Polypharmacy in SLE: How Real Is the Problem?

Related reading

Can Hydroxychloroquine Reduce Risk of Progression to SLE in Patients With…

Lupus prevention remains elusive despite new treatments

‘Orchestra of therapies’ required for most patients with systemic sclerosis

For Youth With SLE, Cognitive Testing Isn't Always on the Docket

Physicians should remember ‘do no harm’ when using compounded medications

Don't Blame DMARDs for Adverse Drug Effects in Rheumatology Patients